Introduction

Africa's reliance on imported medicines and vaccines is staggering, with over 70% of drugs and 99% of vaccines coming from outside the continent. Ghana's President John Dramani Mahama is reframing this reality not as a dead end, but as a massive industrial opening. He argues that the billions spent abroad could instead fuel local manufacturing, jobs, and regional economic growth.

What Happened

Speaking at the Alamein Africa Forum in Egypt, Mahama highlighted that Africa's heavy import dependence has long been viewed through a health-security lens. Yet he insists it should be seen as a signal: the continent already pays heavily for pharmaceuticals, and redirecting that spend toward domestic production could keep value on African soil. The call is for African capital—from commercial banks, sovereign funds, and development institutions—to move into pharma manufacturing, regional supply chains, and health infrastructure.

Why This Matters

Building local pharma capacity could do more than improve health security. It could reduce foreign-exchange pressure, shield health systems from global supply disruptions, and unlock an entirely new industrial layer around manufacturing, logistics, cold chains, diagnostics, and medical technology. Mahama argues that viewing pharmaceuticals as an economic sector—rather than a social cost—could transform Africa's trade balance and create skilled employment across the continent.

Key Takeaways

The path forward requires moving beyond final-assembly manufacturing into active pharmaceutical ingredient production, which demands greater capital, technical expertise, and infrastructure. Regional integration is also critical: when manufacturers can serve multiple African markets, the economics of large-scale plants become viable. Mahama's message is clear—the opportunity is bigger than healthcare; it's about converting existing import spend into domestic industrial capacity.

  • Africa imports over 70% of medicines and 99% of vaccines
  • Local manufacturing could keep value on the continent
  • Regional market integration is key to scaling production
  • Investment must span banks, development funds, and private capital

Conclusion

Africa's dependence on imported medicines isn't disappearing overnight, but the scale of that dependence also reveals the size of the market already available to local manufacturers. If governments, investors, and industry players commit to building domestic pharma capacity, what began as a vulnerability could become one of the continent's most important new industries—driving jobs, trade, and long-term economic resilience.